Abstract | Background:
Glioma-associated macrophages and microglia ( GAMs) are components of the glioblastoma (GBM) microenvironment that express MerTK, a receptor tyrosine kinase that triggers efferocytosis and can suppress innate immune responses. The aim of the study was to define MerTK as a therapeutic target using an orally bioavailable inhibitor, UNC2025. Methods: We examined MerTK expression in tumor cells and macrophages in matched patient GBM samples by double-label immunohistochemistry. UNC2025-induced MerTK inhibition was studied in vitro and in vivo. Results:
MerTK/CD68+ macrophages increased in recurrent tumors while MerTK/ glial fibrillary acidic protein-positive tumor cells did not. Pharmacokinetic studies showed high tumor exposures of UNC2025 in a syngeneic orthotopic allograft mouse GBM model. The same model mice were randomized to receive vehicle, daily UNC2025, fractionated external beam radiotherapy (XRT), or UNC2025/XRT. Although median survival (21, 22, 35, and 35 days, respectively) was equivalent with or without UNC2025, bioluminescence imaging (BLI) showed significant growth delay with XRT/ UNC2025 treatment and complete responses in 19%. The responders remained alive for 60 days and showed regression to 1%-10% of pretreatment BLI tumor burden; 5 of 6 were tumor free by histology. In contrast, only 2% of 98 GBM mice of the same model treated with XRT survived 50 days and none survived 60 days. UNC2025 also reduced CD206+ macrophages in mouse tumor samples. Conclusions: These results suggest that MerTK inhibition combined with XRT has a therapeutic effect in a subset of GBM. Further mechanistic studies are warranted.
|
Authors | Jing Wu, Lauren N Frady, Ryan E Bash, Stephanie M Cohen, Allison N Schorzman, Yu-Ting Su, David M Irvin, William C Zamboni, Xiaodong Wang, Stephen V Frye, Matthew G Ewend, Erik P Sulman, Mark R Gilbert, H Shelton Earp, C Ryan Miller |
Journal | Neuro-oncology
(Neuro Oncol)
Vol. 20
Issue 1
Pg. 92-102
(01 10 2018)
ISSN: 1523-5866 [Electronic] England |
PMID | 28605477
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US. |
Chemical References |
- Piperazines
- UNC2025
- MERTK protein, human
- Mertk protein, mouse
- Receptor Protein-Tyrosine Kinases
- c-Mer Tyrosine Kinase
- Adenine
|
Topics |
- Adenine
(analogs & derivatives, therapeutic use)
- Animals
- Brain Neoplasms
(pathology, therapy)
- Cell Line, Tumor
- Gene Expression Regulation, Neoplastic
(drug effects)
- Glioblastoma
(pathology, therapy)
- Humans
- Mice
- Microglia
(drug effects, metabolism)
- Piperazines
(therapeutic use)
- Receptor Protein-Tyrosine Kinases
(genetics)
- c-Mer Tyrosine Kinase
(drug effects, genetics)
|